The carrying amount of goodwill at June 30, 2020 and March 31, 2020 was $76.8 million and $32.0 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, in May 2005, ECP in July 2014 and Breethe, Inc. in April 2020. The carrying value of goodwill and the change in the balance for the three months ended June 30, 2020 are as follows:

	(in $000's)
Balance, March 31, 2020	$	31,969
Breethe, Inc. acquisition		44,149
Foreign currency translation impact		665
Balance, June 30, 2020	$	76,783

The Company evaluates goodwill at least annually at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. The Company has no accumulated impairment losses on goodwill.

The carrying amount of IPR&D assets at June 30, 2020 and March 31, 2020 was $42.2 million and $14.9 million, respectively, and was recorded in conjunction with the Company’s acquisition of ECP and AIS, in July 2014 and Breethe, Inc, in April 2020.

	June 30, 2020		March 31, 2020
	(in $000's)
ECP	$	15,223	$	14,913
Breethe, Inc.		27,000		—
	$	42,223	$	14,913

The estimated fair value of IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for the future Impella ECP^TM expandable catheter pump and the future OXY-1 system ECMO technology were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used discount rates ranging from 15% to 21% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The carrying value of the Company’s IPR&D assets and the change in the balance for the three months ended June 30, 2020 are as follows:

	(in $000's)
Balance, March 31, 2020	$	14,913
Breethe, Inc. acquisition		27,000
Foreign currency translation impact		310
Balance, June 30, 2020	$	42,223

The Company evaluates IPR&D assets at least annually at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. The Company has no accumulated impairment losses on IPR&D assets.

	June 30, 2020		March 31, 2020
	(in $000's)
Investment in Shockwave Medical	$	79,527	$	55,704
Other investments	$	38,741	$	38,741
Operating lease right of use asset (Note 8)		11,673		11,760
Cross currency swap (Note 6)		1,504		3,786
Other intangible assets and other assets		8,483		7,664
Total other assets	$	139,928	$	117,655

The fair value of the Company’s investment in Shockwave Medical, a publicly-traded medical device company, was $79.5 million and $55.7 million as of June 30, 2020 and March 31, 2020, respectively. Amounts recorded in other income were $23.8 million and $39.7 million for the three months ended June 30, 2020 and 2019, respectively.

The carrying value of the Company’s portfolio of other investments and the change in the balance for the three months ended June 30, 2020 and 2019 are as follows:

	For the Three Months Ended June 30,
		2020			2019
	(in $000's)
Beginning balance	$	38,741		$	24,584
Additions		2,000			2,000
Reclassification		(2,000	)		—
Change in fair value, net		—			—
Ending balance	$	38,741		$	26,584

Included within other intangible assets and other is $4.1 million related to license manufacturing rights to certain technology from third parties. These intangible assets are classified with other assets in the Company’s consolidated balance sheet and are amortized over their useful life of 15 years.